The Lancet Voice

Gavin is joined once again by Richard and Jessamy as they examine key developments in global health and science. This week"s discussion features reflections on the launch of a new Lancet series on Alzheimer’s disease, highlighting advances in prevention, diagnosis, and care, as well as the ethical and practical challen

Gavin welcomes Walter Willett, Shakuntala Thilsted and Johan Rockström to discuss the second EAT-Lancet Commission report. The co-chairs explain the significant updates since the inaugural 2019 commission, including new global evidence on nutrition, advances in food systems modelling, and a greater focus on equity and

Scientific research has traditionally treated the male body as the default, resulting in health inequity and poor outcomes for women in a world not designed for them. The Sex and Gender Equity in Research (SAGER) guidelines are an attempt to make sure research is designed for everyone, and that the outcomes better serv

Gavin, Richard, and Jessamy enter the studio once more for a Lancet Voice chat. A new book on Alzheimer"s disease causes controversy across the Lancet team, we discuss the new Countdown on Plastics & Health, and a quick look at the problems facing the upcoming UN High Level Meeting on NCDs. You can read the Lancet Coun

Where did the 10,000 steps recommendation come from? Why has it proven so stubborn? What"s the science behind the new recommendations? How strong is the evidence? Professor Melody Ding joins Gavin to talk about her new systematic review published in The Lancet Public Health, examining the relationship between step coun

It’s no exaggeration to say that the past decade has revolutionized how we think about and treat obesity. Drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) have dominated headlines, enabling significant weight loss at speeds once considered unthinkable. The market for innovative weight loss medications is boom